These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35979678)

  • 1. Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation.
    Braghieri L; Jennings DL; Bohn B; Habal M; Pinsino A; Mondellini GM; Ladanyi A; Latif F; Clerkin K; Restaino S; Kurlansky P; Takeda K; Naka Y; Demmer RT; Sayer GT; Uriel N; Colombo PC; Yuzefpolskaya M
    Pharmacotherapy; 2022 Sep; 42(9):697-706. PubMed ID: 35979678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P; Cravedi P; Gotti E; Plati A; Marasà M; Sandrini S; Bossini N; Citterio F; Minetti E; Montanaro D; Sabadini E; Tardanico R; Martinetti D; Gaspari F; Villa A; Perna A; Peraro F; Remuzzi G
    PLoS Med; 2021 Jun; 18(6):e1003668. PubMed ID: 34166370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
    Kiberd BA; Lawen J; Daley C
    Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
    Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
    Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Mathew TH
    Transplantation; 1998 Jun; 65(11):1450-4. PubMed ID: 9645801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
    Triemer HL; Pearson TC; Odom KL; Larsen CP
    Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil without antibody induction in cadaver vs. living donor pediatric renal transplantation.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W
    Pediatr Transplant; 2003 Apr; 7(2):137-41. PubMed ID: 12654055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
    Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
    Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
    Remuzzi G; Cravedi P; Costantini M; Lesti M; Ganeva M; Gherardi G; Ene-Iordache B; Gotti E; Donati D; Salvadori M; Sandrini S; Segoloni G; Federico S; Rigotti P; Sparacino V; Ruggenenti P
    J Am Soc Nephrol; 2007 Jun; 18(6):1973-85. PubMed ID: 17460145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.
    Moreso F; Serón D; Morales JM; Cruzado JM; Gil-Vernet S; Pérez JL; Fulladosa X; Andrés A; Grinyó JM
    Clin Transplant; 1998 Jun; 12(3):198-205. PubMed ID: 9642510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.